Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)
Status:
Terminated
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
Evaluation of unfavourable outcome-related factors in patients affected by renal cell cancer
in treatment with everolimus and previously treated with a Vascular endothelial growth factor
(VEGF) inhibitor (i.e. sunitinib, sorafenib,pazopanib, or bevacizumab+interferon)
Phase:
Phase 4
Details
Lead Sponsor:
Mario Negri Institute for Pharmacological Research